查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088828

重症肌無力治療市場：依治療分類、疾病類型、給藥途徑、通路及最終用戶分類－2026-2032年全球市場預測

Myasthenia Gravis Treatment Market by Treatment Class, Disease Type, Administration Route, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，重症肌無力治療市場規模將成長至 27.1 億美元，複合年成長率為 7.88%。

主要市場統計數據
基準年 2025 15.9億美元
預計年份：2026年 17.1億美元
預測年份 2032 27.1億美元
複合年成長率 (%) 7.88%

重症肌無力的治療正從廣泛的免疫抑制療法轉向標靶的、基於生物標記的療法。此病是一種慢性自體免疫神經肌肉疾病，其特徵是骨骼肌無力波動，常涉及眼肌、延髓肌、四肢肌和呼吸肌肉。包括乙醯膽鹼酯酶抑制劑、皮質類固醇、非類固醇類免疫抑制劑、胸腺切除術、靜脈注射免疫球蛋白和血漿置換在內的標準療法仍發揮重要作用，尤其是在急性惡化期和全身型重症肌無力的治療中。

FDA批准和EMA審查的生物製藥正在改變治療格局，這些製劑作用於補體活化和新生兒Fc受體路徑。 Eculizumab、lavlizumab、efgaltigimod、rozanolixizumab和zircoplan拓展了乙醯膽鹼受體抗體陽性疾病的治療選擇，並在某些適應症中，使其能夠應用於更廣泛的、由抗體定義的患者群體。這些進展推動了對早期診斷、抗體檢測、專科神經科診療、保險公司所需證據以及長期安全性監測的需求不斷成長。

治療前景的突破性轉變

重症肌無力治療領域最顯著的變化是從症狀控制轉向緩解疾病的免疫調節。補體C5抑制劑和FcRn阻斷劑在檢驗的終點指標（例如重症肌無力日常生活活動能力評分和定量重症肌無力評分）方面均顯示出具有臨床意義的改善，這支持為全身型重症肌無力患者制定更加個體化的治療方案。

人工智慧的累積影響

人工智慧在重症肌無力治療價值鏈的各個環節中發揮日益重要的作用，尤其是在早期檢測、患者分層、臨床試驗最佳化和藥物安全監測方面。將機器學習應用於計費資料、電子健康記錄、神經科病歷和實驗室結果模式，可以識別漏診患者並預測症狀加重的風險。此外，利用自然語言處理技術，可以從非結構化的臨床記錄中提取肌肉無力、吞嚥困難、複視、機械呼吸系統護理和緊急治療等症狀模式。

關鍵區域洞察

北美憑藉其專業的神經科醫療基礎設施、生物製藥的早期核准、成熟的保險體係以及積極參與臨床試驗，仍然是重症肌無力治療藥物引進的領先地區。在美國，補體抑制劑和FcRn抑制劑的快速應用構成了市場需求的基礎；而在加拿大，實證報銷、省級准入途徑以及由專科醫生主導的全身型重症肌無力治療方案則更為重要。

關鍵群體特定見解

七國集團（G7）在進行性重症肌無力治療藥物的引進方面佔據重要佔有率，這得益於其完善的醫療網路、成熟的監管體系、積極的臨床試驗參與以及對罕見疾病和特殊神經系統疾病治療的報銷能力。歐盟透過集中核准藥品和在國家層級進行價格談判發揮核心作用，而北約成員國的市場與高所得的醫療保健體系高度重疊，這些體系為先進的免疫學和神經肌肉疾病治療提供資金。

主要國家的關鍵見解

美國在臨床創新和先進療法引進方面處於主導地位，這得益於FDA的批准、專科藥房、神經肌肉疾病中心以及真實世界數據（REW）的累積。加拿大採用了系統化的報銷機制，而墨西哥和巴西則透過私部門的准入、公共專科計畫以及神經科醫生認知度的提高而發展壯大。在英國、德國、法國、義大利和西班牙，相關政策由國家評估機構制定，這些機構優先考慮臨床效益、預算影響、治療順序和真實世界結果。俄羅斯在區域准入規劃中仍然佔據重要地位，但面臨著與採購、報銷和地緣政治因素相關的複雜挑戰。

為行業領導者提供的實用建議

產業領導者應優先考慮能夠證明持續控制症狀、減少病情加重、減少類固醇用量、改善日常生活功能以及降低對搶救療法依賴性的證據包。支付者越來越關注高階生物製藥是否能夠減少住院、重症監護、血漿置換、靜脈注射免疫球蛋白的依賴以及長期使用皮質類固醇的負擔。因此，必須將真實世界證據納入產品上市和生命週期規劃中。

調查方法

本執行摘要透過對公開的監管記錄、同行檢驗的神經病學文獻、臨床試驗註冊數據、治療指南、衛生技術評估 (HTA) 結果以及已通過核准的治療組進行三角分析而編寫。重點關注已檢驗的臨床終點、抗體定義的目標人群、作用機制的差異、區域可及性趨勢以及醫療服務提供方面的可觀察變化。

結論

重症肌無力的治療正步入一個更具針對性和競爭性的時代，補體和FcRn抑制劑的出現重新定義了人們對疾病整體管理的預期。儘管傳統療法仍然至關重要，但治療重點正轉向精準免疫學、檢驗的療效指標、個人化治療方案以及以患者為中心的護理模式。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 重症肌無力治療市場：依治療分類

  • 乙醯膽鹼酯酶抑制劑
  • 免疫抑制劑
    • 皮質類固醇
    • 非類固醇免疫抑制劑
  • 靜脈注射免疫球蛋白
  • 單株抗體
  • 血漿置換

第8章：重症肌無力治療市場：依疾病類型分類

  • 全身型重症肌無力
  • 眼肌型重症肌無力
  • 早髮型重症肌無力

第9章：重症肌無力治療市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 皮下

第10章：重症肌無力治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章：重症肌無力治療市場：依最終使用者分類

  • 診所
  • 居家照護
  • 醫院

第12章：重症肌無力治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：重症肌無力治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 重症肌無力治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • AstraZeneca PLC
  • argenx SE
  • UCB SA
  • Johnson & Johnson Services Inc.
  • Novartis AG
  • Grifols, SA
  • Takeda Pharmaceutical Company Limited
  • F. Hoffmann-La Roche Ltd.
  • Bausch Health Companies Inc.
  • Catalyst Pharmaceuticals, Inc.
  • Dr. Reddy's Laboratories Limited
  • Teva Pharmaceutical Industries Ltd.
  • Amgen Inc.
  • Arcellx, Inc.
  • Asahi Kasei Medical Co., Ltd.
  • Hikma Pharmaceuticals PLC
  • Immunovant Sciences GmbH
  • Merck KGaA
  • Regeneron Pharmaceuticals, Inc.
  • Terumo BCT, Inc.
Product Code: MRR-0A609A26A9B8

The Myasthenia Gravis Treatment Market is projected to grow by USD 2.71 billion at a CAGR of 7.88% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.59 billion
Estimated Year [2026] USD 1.71 billion
Forecast Year [2032] USD 2.71 billion
CAGR (%) 7.88%

Myasthenia gravis treatment is moving from broad immunosuppression toward targeted, biomarker-informed care for a chronic autoimmune neuromuscular disorder that causes fluctuating skeletal muscle weakness, most often involving ocular, bulbar, limb, and respiratory muscles. Standard therapies such as acetylcholinesterase inhibitors, corticosteroids, steroid-sparing immunosuppressants, thymectomy, intravenous immunoglobulin, and plasma exchange remain important, especially for acute exacerbations and generalized myasthenia gravis.

The treatment landscape is being reshaped by U.S. FDA- and EMA-reviewed biologics that address complement activation and neonatal Fc receptor pathways. Eculizumab, ravulizumab, efgartigimod, rozanolixizumab, and zilucoplan have expanded options for acetylcholine receptor antibody-positive disease and, in selected indications, broader antibody-defined populations. These advances are increasing demand for earlier diagnosis, antibody testing, specialty neurology access, payer evidence, and long-term safety monitoring.

Transformative Shifts in the Treatment Landscape

The most important shift in the myasthenia gravis treatment landscape is the transition from symptom control to disease-modifying immune modulation. Complement C5 inhibition and FcRn blockade have demonstrated clinically meaningful improvements in validated endpoints such as Myasthenia Gravis Activities of Daily Living and Quantitative Myasthenia Gravis scores, supporting more personalized treatment sequencing for generalized myasthenia gravis.

Healthcare systems are also shifting from episodic rescue care to proactive management of chronic autoimmune neuromuscular disease. Specialty infusion networks, subcutaneous and self-administration options, real-world evidence programs, and patient-reported outcome tracking are becoming competitive differentiators. At the same time, high-cost biologics are intensifying payer scrutiny, making comparative effectiveness, durability of response, relapse prevention, corticosteroid reduction, and quality-of-life evidence central to market access.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly relevant across the myasthenia gravis treatment value chain, particularly in earlier recognition, patient stratification, trial optimization, and pharmacovigilance. Machine learning applied to claims data, electronic health records, neurology notes, and laboratory patterns can help identify underdiagnosed patients and predict risk of exacerbation, while natural language processing can extract weakness patterns, dysphagia, diplopia, ventilatory support, and rescue therapy events from unstructured clinical documentation.

AI is also improving clinical development efficiency by supporting site selection, protocol feasibility, synthetic control exploration, patient-reported outcome analysis, and adverse-event signal detection. However, regulated clinical decision-making still requires physician oversight, transparent validation, bias testing, explainable models, and compliance with privacy frameworks such as HIPAA and GDPR. Leaders that combine AI with clinically curated datasets will be better positioned to generate evidence that clinicians, regulators, and payers trust.

Key Regional Insights

North America remains a leading region for myasthenia gravis treatment adoption due to specialty neurology infrastructure, early biologic approvals, mature payer systems, and strong clinical trial participation. The United States anchors demand through rapid uptake of complement inhibitors and FcRn inhibitors, while Canada emphasizes evidence-based reimbursement, provincial access pathways, and specialist-led treatment protocols for generalized myasthenia gravis.

Europe is characterized by EMA authorization, national health technology assessment, and increasing emphasis on cost-effectiveness, with Germany, France, Italy, Spain, and the United Kingdom shaping access models through clinical benefit assessment, pricing negotiation, and real-world evidence requirements. Asia-Pacific is expanding as Japan, China, Australia, South Korea, and India improve antibody testing, diagnosis, rare disease pathways, and specialist capacity. Latin America shows rising clinical need through Brazil and Mexico, but access varies between public and private channels. The Middle East, led by high-investment tertiary care systems, is strengthening access to advanced neurology therapies, while Africa continues to face constraints related to diagnostic availability, specialist density, reimbursement, and supply chain reliability.

Key Group Insights

The G7 accounts for a major portion of advanced myasthenia gravis treatment adoption because its members combine specialty care networks, regulatory maturity, clinical trial participation, and reimbursement capacity for rare and specialty neurology therapies. The European Union plays a central role through centralized medicine authorization and country-level pricing negotiations, while NATO markets overlap substantially with higher-income healthcare systems that fund advanced immunology and neuromuscular disease treatments.

BRICS countries represent a long-term growth engine for myasthenia gravis treatment access, led by China, India, and Brazil, where rising diagnosis rates, healthcare investment, and expanding specialty care are increasing treated patient visibility. ASEAN markets are improving access through specialist hospital networks and public-sector modernization, although reimbursement and diagnostic availability remain heterogeneous. GCC countries benefit from centralized purchasing, tertiary care investment, and national strategies for specialty medicine access, supporting adoption of advanced therapies for severe generalized myasthenia gravis.

Key Country Insights

The United States leads in clinical innovation and advanced therapy adoption, supported by FDA approvals, specialty pharmacies, neuromuscular centers, and real-world evidence generation. Canada follows a structured reimbursement approach, while Mexico and Brazil are growing through private-sector access, public specialty programs, and increasing neurologist awareness. The United Kingdom, Germany, France, Italy, and Spain are shaped by national assessment bodies that prioritize clinical benefit, budget impact, treatment sequencing, and real-world outcomes. Russia remains relevant in regional access planning but faces complexity linked to procurement, reimbursement, and geopolitical factors.

China, Japan, India, Australia, and South Korea are central to Asia-Pacific expansion in myasthenia gravis treatment. Japan has strong rare disease and neurology infrastructure, China is scaling biologic access through regulatory modernization and hospital-based specialty care, and India offers large unmet need with affordability and diagnostic constraints. Australia and South Korea combine specialist capacity with evidence-based reimbursement and high-quality tertiary care, supporting broader use of advanced therapies where clinical and payer criteria are met.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence packages that demonstrate sustained symptom control, reduced exacerbations, steroid-sparing effects, improved daily functioning, and lower rescue therapy dependence. Payers are increasingly asking whether premium biologics reduce hospitalizations, intensive care use, plasma exchange, intravenous immunoglobulin reliance, and long-term corticosteroid burden, so real-world evidence should be built into launch and lifecycle plans.

Organizations should also invest in antibody testing pathways, physician education, patient support services, and differentiated administration models, including infusion, subcutaneous, and self-administration options where approved. Strategic partnerships with neuromuscular centers, specialty pharmacies, patient registries, and data platforms can accelerate diagnosis and improve adherence. For emerging markets, tiered access strategies, local evidence generation, diagnostic capacity building, and health-system partnerships will be essential to responsible growth.

Research Methodology

This executive summary is informed by triangulation of public regulatory records, peer-reviewed neurology literature, clinical trial registries, treatment guidelines, health technology assessment outputs, and published evidence on approved therapeutic classes. Emphasis was placed on validated clinical endpoints, antibody-defined populations, mechanism-of-action differentiation, regional access dynamics, and observable shifts in care delivery.

The research approach applies secondary data review, market structure analysis, therapy-class mapping, regional comparison, and expert interpretation of commercialization factors. Data points were assessed for consistency across authoritative sources such as FDA, EMA, clinical guideline bodies, clinical trial publications, and health technology assessment reports. Forward-looking insights are framed as evidence-based interpretations of current treatment and access trends rather than unsupported forecasts.

Conclusion

Myasthenia gravis treatment is entering a more targeted and competitive era, with complement inhibitors and FcRn inhibitors redefining expectations for generalized disease management. Conventional therapy remains foundational, but the center of gravity is shifting toward precision immunology, validated outcome measurement, individualized sequencing, and patient-centered care models.

Success in the global myasthenia gravis treatment landscape will depend on more than clinical efficacy. Leaders must demonstrate long-term value, streamline diagnosis, expand antibody testing, manage biologic access, and generate credible real-world evidence across diverse healthcare systems. Organizations that integrate science, data, affordability, and patient support will be best positioned as care for myasthenia gravis continues to evolve.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Myasthenia Gravis Treatment Market, by Treatment Class

  • 7.1. Acetylcholinesterase Inhibitors
  • 7.2. Immunosuppressants
    • 7.2.1. Corticosteroids
    • 7.2.2. Nonsteroidal Immunosuppressants
  • 7.3. Intravenous Immunoglobulin
  • 7.4. Monoclonal Antibodies
  • 7.5. Plasma Exchange

8. Myasthenia Gravis Treatment Market, by Disease Type

  • 8.1. Generalized Myasthenia Gravis
  • 8.2. Ocular Myasthenia Gravis
  • 8.3. Juvenile-Onset Myasthenia Gravis

9. Myasthenia Gravis Treatment Market, by Administration Route

  • 9.1. Intravenous
  • 9.2. Oral
  • 9.3. Subcutaneous

10. Myasthenia Gravis Treatment Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Online Pharmacies
  • 10.3. Retail Pharmacies

11. Myasthenia Gravis Treatment Market, by End User

  • 11.1. Clinics
  • 11.2. Home Care
  • 11.3. Hospitals

12. Myasthenia Gravis Treatment Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Myasthenia Gravis Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Myasthenia Gravis Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. AstraZeneca PLC
  • 16.2. argenx SE
  • 16.3. UCB S.A.
  • 16.4. Johnson & Johnson Services Inc.
  • 16.5. Novartis AG
  • 16.6. Grifols, S.A.
  • 16.7. Takeda Pharmaceutical Company Limited
  • 16.8. F. Hoffmann-La Roche Ltd.
  • 16.9. Bausch Health Companies Inc.
  • 16.10. Catalyst Pharmaceuticals, Inc.
  • 16.11. Dr. Reddy's Laboratories Limited
  • 16.12. Teva Pharmaceutical Industries Ltd.
  • 16.13. Amgen Inc.
  • 16.14. Arcellx, Inc.
  • 16.15. Asahi Kasei Medical Co., Ltd.
  • 16.16. Hikma Pharmaceuticals PLC
  • 16.17. Immunovant Sciences GmbH
  • 16.18. Merck KGaA
  • 16.19. Regeneron Pharmaceuticals, Inc.
  • 16.20. Terumo BCT, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ACETYLCHOLINESTERASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ACETYLCHOLINESTERASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ACETYLCHOLINESTERASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IMMUNOSUPPRESSANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMMUNOSUPPRESSANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IMMUNOSUPPRESSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NONSTEROIDAL IMMUNOSUPPRESSANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NONSTEROIDAL IMMUNOSUPPRESSANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NONSTEROIDAL IMMUNOSUPPRESSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PLASMA EXCHANGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PLASMA EXCHANGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PLASMA EXCHANGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENERALIZED MYASTHENIA GRAVIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GENERALIZED MYASTHENIA GRAVIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENERALIZED MYASTHENIA GRAVIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL OCULAR MYASTHENIA GRAVIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL OCULAR MYASTHENIA GRAVIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL OCULAR MYASTHENIA GRAVIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL JUVENILE-ONSET MYASTHENIA GRAVIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL JUVENILE-ONSET MYASTHENIA GRAVIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL JUVENILE-ONSET MYASTHENIA GRAVIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HOME CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HOME CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HOME CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. GCC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 116. GCC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 117. GCC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 118. GCC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. GCC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 120. GCC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. GCC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. G7 MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. G7 MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 138. G7 MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 139. G7 MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. G7 MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 141. G7 MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. G7 MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. NATO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 144. NATO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 145. NATO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 146. NATO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. NATO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 148. NATO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. NATO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 160. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 161. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 163. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 166. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 167. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 168. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 170. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 174. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 175. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 177. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 187. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 188. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 189. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 191. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 195. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 196. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 198. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 201. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 202. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 203. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 205. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 208. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 209. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 210. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 212. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 216. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 217. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 219. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 220. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. INDIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 229. INDIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 230. INDIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 231. INDIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. INDIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 233. INDIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. INDIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 237. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 238. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 240. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 241. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. AUSTRALIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. AUSTRALIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 244. AUSTRALIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 245. AUSTRALIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. AUSTRALIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 247. AUSTRALIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 248. AUSTRALIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. SOUTH KOREA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 250. SOUTH KOREA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 251. SOUTH KOREA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 252. SOUTH KOREA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. SOUTH KOREA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 254. SOUTH KOREA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 255. SOUTH KOREA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)